A novel coronavirus causing severe acute respiratory syndrome (SARS), named SARS-CoV-2, was identified at the end of 2019. The spread of coronavirus disease 2019 (COVID-19) has progressively expanded from China, involving several countries throughout the world, leading to the classification of the disease as a pandemic by the World Health Organization (WHO). According to published reports, COVID-19 severity and mortality are higher in elderly patients and those with active comorbidities. In particular, lung cancer patients were reported to be at high risk of pulmonary complications related to SARS-CoV2 infection. Therefore, the management of cancer care during the COVID-19 pandemic is a crucial issue, to which national and international oncology organizations have replied with recommendations concerning patients receiving anticancer treatments, delaying follow-up visits and limiting caregiver admission to the hospitals. In this historical moment, medical oncologists are required to consider the possibility to delay active treatment administration based on a case-by-case risk/benefit evaluation. Potential risks associated with COVID-19 infection should be considered, considering tumor histology and natural course, disease setting, clinical conditions, and disease burden, together with the expected benefit, toxicities (e.g., myelosuppression or interstitial lung disease), and response obtained from the planned or ongoing treatment. In this study, we report the results of proactive measures including social media, telemedicine, and telephone triage for screening patients with lung cancer during the COVID-19 outbreak in the European Institute of Oncology (Milan, Italy). Proactive management and containment measures, applied in a structured and daily way, has significantly aided the identification of advance patients with suspected symptoms related to COVID-19, limiting their admission to our cancer center; we have thus been more able to protect other patients from possible contamination and at the same time guarantee to the suspected patients the immediate treatment and evaluation in referral hospitals for COVID-19.

Results of multilevel containment measures to better protect lung cancer patients from COVID-19. the IEO model / de Marinis, Filippo; Attili, Ilaria; Morganti, Stefania; Stati, Valeria; Spitaleri, Gianluca; Gianoncelli, Letizia; Del Signore, Ester; Catania, Chiara; Rampinelli, Cristiano; Omodeo Sale, Emanuela; Spaggiari, Lorenzo; Mastrilli, Fabrizio; Passaro, Antonio. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 10:(2020), pp. 1-10. [10.3389/fonc.2020.00665]

Results of multilevel containment measures to better protect lung cancer patients from COVID-19. the IEO model

Stati Valeria;
2020

Abstract

A novel coronavirus causing severe acute respiratory syndrome (SARS), named SARS-CoV-2, was identified at the end of 2019. The spread of coronavirus disease 2019 (COVID-19) has progressively expanded from China, involving several countries throughout the world, leading to the classification of the disease as a pandemic by the World Health Organization (WHO). According to published reports, COVID-19 severity and mortality are higher in elderly patients and those with active comorbidities. In particular, lung cancer patients were reported to be at high risk of pulmonary complications related to SARS-CoV2 infection. Therefore, the management of cancer care during the COVID-19 pandemic is a crucial issue, to which national and international oncology organizations have replied with recommendations concerning patients receiving anticancer treatments, delaying follow-up visits and limiting caregiver admission to the hospitals. In this historical moment, medical oncologists are required to consider the possibility to delay active treatment administration based on a case-by-case risk/benefit evaluation. Potential risks associated with COVID-19 infection should be considered, considering tumor histology and natural course, disease setting, clinical conditions, and disease burden, together with the expected benefit, toxicities (e.g., myelosuppression or interstitial lung disease), and response obtained from the planned or ongoing treatment. In this study, we report the results of proactive measures including social media, telemedicine, and telephone triage for screening patients with lung cancer during the COVID-19 outbreak in the European Institute of Oncology (Milan, Italy). Proactive management and containment measures, applied in a structured and daily way, has significantly aided the identification of advance patients with suspected symptoms related to COVID-19, limiting their admission to our cancer center; we have thus been more able to protect other patients from possible contamination and at the same time guarantee to the suspected patients the immediate treatment and evaluation in referral hospitals for COVID-19.
2020
cancer; containment measures; coronavirus; covid-19; lung cancer
01 Pubblicazione su rivista::01a Articolo in rivista
Results of multilevel containment measures to better protect lung cancer patients from COVID-19. the IEO model / de Marinis, Filippo; Attili, Ilaria; Morganti, Stefania; Stati, Valeria; Spitaleri, Gianluca; Gianoncelli, Letizia; Del Signore, Ester; Catania, Chiara; Rampinelli, Cristiano; Omodeo Sale, Emanuela; Spaggiari, Lorenzo; Mastrilli, Fabrizio; Passaro, Antonio. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 10:(2020), pp. 1-10. [10.3389/fonc.2020.00665]
File allegati a questo prodotto
File Dimensione Formato  
fonc-10-00665.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 469.9 kB
Formato Adobe PDF
469.9 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1485698
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 18
social impact